Adverse Events With Sustained-Release Donepezil in Alzheimer Disease

Purpose/Background Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trial, body weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures To clarify whether this finding is consistent across ethnic groups that vary in absolute body mass, we recruited Korean...